Sept. 24 (UPI) -- People with COVID-19 may be at increased risk for developing Guillain-Barre syndrome, a study published Friday by the journal Brain found.

A new study indicates that COVID-19 is associated with an elevated risk of a rare disorder, Guillain-Barré syndrome, within six weeks after infection with the virus.

Reference: Nasreen S, Jiang Y, Lu H, et al. Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study. Vaccine.

Guillain-Barré and Vaccines: What You Need to Know The link between the rare neurological disorder and the Johnson & Johnson Covid-19 vaccine may be real, but the risk appears to be very small.

Two studies published in Annals of Neurology reported small clusters “of an unusual variant of Guillain-Barre syndrome” following receipt of a COVID-19 vaccine, according to a press release ...

Having a COVID-19 infection is associated with an increased risk of developing the rare disorder called Guillain-Barré syndrome within the next six weeks, according to a study published in the ...

The study tracked millions of people in Israel, finding that those with a recent history of covid-19 infection were noticeably more likely to develop Guillain-Barré than those without one.

A new multinational study analyzing data from over 230 million people across 20 global sites highlights the relationship between SARS-CoV-2 infection, certain COVID-19 vaccines, and Guillain ...

The odds of developing Guillain-Barré syndrome after getting the COVID-19 shot, they say, are less than getting it from other vaccines, bacteria and viruses, including SARS-CoV-2, the virus that ...

Johnson & Johnson’s beleaguered Covid-19 vaccine may be associated with a small increased risk of Guillain-Barré syndrome, a rare but potentially serious neurological condition, federal ...

Coronavirus J&J COVID-19 vaccine benefits ‘far outweigh’ risks, CDC panel says after reports of Guillain-Barré syndrome Researchers noted a reporting rate of 8.1 GBS cases per million J&J ...

J&J has administered 12.8 million doses of its vaccine, and there have been 100 reported cases of Guillain-Barre syndrome. Even so, that’s not quite 0.0008 percent of the people who received the ...